首頁 > 市場調查報告書 > 製藥

勃起功能障礙藥物市場規模、佔有率和成長分析（按類型、給藥途徑、通路和地區分類）—產業預測（2026-2033 年）

市場調查報告書

商品編碼

1900266

勃起功能障礙藥物市場規模、佔有率和成長分析（按類型、給藥途徑、通路和地區分類）—產業預測（2026-2033 年）

Erectile Dysfunction Drugs Market Size, Share, and Growth Analysis, By Type (Viagra (Sildenafil Citrate), Cialis (Tadalafil)), By Route of Administration, By Distribution Channel, By Region -Industry Forecast 2026-2033

出版日期: 2025年12月18日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，治療勃起功能障礙的藥物市場規模將達到 28.6 億美元，到 2025 年將成長至 31.2 億美元，到 2033 年將成長至 63.1 億美元，在預測期（2026-2033 年）內複合年成長率為 9.2%。

勃起功能障礙（ED）發生率的上升是推動勃起功能障礙治療市場成長的主要因素。這種影響相當一部分男性的疾病由多種因素引起，包括糖尿病、心血管疾病和心理壓力。尤其值得注意的是，ED的盛行率與老齡化相關的生理變化和慢性疾病密切相關，而這些因素在老年人中日益普遍。身心健康之間的相互關聯進一步加劇了這個問題，而多種藥物也可能導致勃起功能障礙。藥物輸送技術的進步、人們對ED影響生活品質的認知不斷提高以及醫療保健服務的改善，都在推動對有效藥物解決方案的需求，因此，持續的研發對於市場擴張至關重要。

治療勃起功能障礙藥物的市場促進因素

全球勃起功能障礙藥物市場的主要促進因素是性功能障礙盛行率的不斷上升，而這又歸因於人口老化、久坐不動的生活方式以及糖尿病和心血管疾病等慢性病發病率的增加。人們對這些性問題的認知和接受度不斷提高，推動了對有效治療方法的需求。此外，透過加強教育和溝通來消除對勃起功能障礙的歧視，有助於促進更開放的對話，並鼓勵男性尋求醫療建議和治療。因此，製藥公司越來越重視開發創新治療方法，進一步推動了市場成長。

限制勃起功能障礙治療市場的因素

全球勃起功能障礙治療市場的主要限制因素之一是人們對非藥物療法的認知度和接受度不斷提高。隨著越來越多的患者尋求包括生活方式調整、諮詢和自然療法在內的整體治療方法，他們對傳統藥物的依賴性可能會降低。此外，對潛在副作用的擔憂以及因治療勃起功能障礙而產生的社會污名，也可能進一步抑制市場成長。另外，遠端醫療服務的日益普及可能會促使患者更謹慎地探索替代療法，從而降低對處方藥的需求。這給市場上的現有製藥公司帶來了挑戰。

勃起功能障礙治療市場趨勢

勃起功能障礙藥物市場正經歷重大變革，其驅動力包括非處方藥（OTC）的出現和消費者獲取途徑的增加。這一趨勢的特點是，製藥公司積極研發和推廣廣受歡迎的非處方箋勃起功能障礙藥物，旨在覆蓋更廣泛的客戶群體，包括那些偏好非處方藥購買方式的消費者，因為這種方式更加注重隱私和便利。這種演變在法規結構較為完善的地區尤其明顯，反映出人們對勃起功能障礙藥物的接受度不斷提高，以及對男性健康問題的日益關注。最終，其目標是消除圍繞治療方案的偏見，並促進積極主動的健康管理。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭格局

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市集活動
主要企業市佔率（2025 年）

主要企業簡介

Merck & Co., Inc.（US）
Bausch Health Companies Inc.（Canada）
Hims, Inc.（US）
Sildenafil Therapeutics LLC（US）
Eli Lilly and Company（US）
MediSprout（US）
NantKwest, Inc.（US）
Cipla Limited（India）
Apexigen, Inc.（US）
NantWorks LLC（US）
Sorrento Therapeutics, Inc.（US）
Tetra Bio-Pharma Inc.（Canada）
Merck & Co., Inc.（US）
Bausch Health Companies Inc.（Canada）
Hims, Inc.（US）
Sildenafil Therapeutics LLC（US）
Eli Lilly and Company（US）
MediSprout（US）
NantKwest, Inc.（US）
Cipla Limited（India）
Apexigen, Inc.（US）
NantWorks LLC（US）
Sorrento Therapeutics, Inc.（US）
Tetra Bio-Pharma Inc.（Canada）

簡介目錄

Product Code: SQMIG35I2259

Erectile Dysfunction Drugs Market size was valued at USD 2.86 Billion in 2024 and is poised to grow from USD 3.12 Billion in 2025 to USD 6.31 Billion by 2033, growing at a CAGR of 9.2% during the forecast period (2026-2033).

The rising incidence of erectile dysfunction (ED) is significantly propelling the growth of the erectile dysfunction drugs market. This condition, affecting a considerable percentage of men, is influenced by a range of factors such as diabetes, cardiovascular issues, and psychological stress. Notably, the prevalence of ED is closely tied to age-related physiological changes and chronic illnesses, which are increasingly common among older populations. The interconnected nature of physical and mental health further exacerbates this issue, with various medications potentially contributing to erectile difficulties. The demand for effective pharmaceutical solutions is increasing, driven by advancements in drug delivery technologies, greater awareness of ED's impact on quality of life, and enhanced healthcare access, making ongoing research and development critical for market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Erectile Dysfunction Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Erectile Dysfunction Drugs Market Segments Analysis

Global Erectile Dysfunction Drugs Market is segmented by Type, Route of Administration, and region. Based on Type, the market is segmented into Viagra (sildenafil citrate), Cialis (Tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), and Other Drugs. Based on Route of Administration, the market is segmented into Oral Mode of Administration, Injectable Mode of Administration, and Other Modes of Administration. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Erectile Dysfunction Drugs Market

A key market driver for the global erectile dysfunction drugs market is the increasing prevalence of sexual health disorders, driven by factors such as aging populations, sedentary lifestyles, and rising rates of chronic diseases like diabetes and cardiovascular issues. This growing awareness and acceptance of sexual health challenges have led to higher demand for effective treatment options. Additionally, the destigmatization of erectile dysfunction through improved education and communication fosters a more open dialogue, encouraging men to seek medical advice and treatment. As a result, pharmaceutical companies are increasingly focused on developing innovative therapies, further propelling market growth.

Restraints in the Erectile Dysfunction Drugs Market

One key market restraint for the global erectile dysfunction drugs market is the growing awareness and acceptance of non-pharmaceutical treatment options. As more patients seek holistic approaches, such as lifestyle modifications, counseling, and natural remedies, reliance on traditional medications may decline. Additionally, concerns regarding potential side effects and the stigma associated with seeking treatment for erectile dysfunction can further inhibit market growth. Moreover, the increasing preference for telehealth services allows patients to explore alternative treatments more discreetly, which can limit the demand for prescription medications, thereby posing a challenge to the established pharmaceutical players in the market.

Market Trends of the Erectile Dysfunction Drugs Market

The erectile dysfunction drugs market is witnessing a significant shift with the emergence of over-the-counter (OTC) options, enhancing accessibility for consumers. This trend is characterized by pharmaceutical companies actively pursuing the development and marketing of popular ED medications without the need for prescriptions. By doing so, they aim to tap into a wider demographic, catering to individuals who may prefer the privacy and convenience of OTC purchases. This evolution is particularly pronounced in regions with progressive regulatory frameworks, reflecting a broader acceptance of ED medications and a growing recognition of men's health issues, ultimately aiming to destigmatize treatment options and encourage proactive health management.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Ecosystem of the Market
Case study Analysis
PESTEL Analysis
Regulatory Landscape
Top Investment Analysis
Key Success Factor
Degree of Competition

Erectile Dysfunction Drugs Market by Product

Market Overview
Viagra (sildenafil citrate)
Cialis (Tadalafil)
Levitra/Staxyn (vardenafil)
Stendra/Spedra (avanafil)
Zydena (udenafil)
Other Drugs

Erectile Dysfunction Drugs Market by Route of Administration

Market Overview
Oral Mode of Administration
Injectable Mode of Administration
Other Modes of Administration

Erectile Dysfunction Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hims, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sildenafil Therapeutics LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MediSprout (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantKwest, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Apexigen, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantWorks LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sorrento Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tetra Bio-Pharma Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hims, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sildenafil Therapeutics LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MediSprout (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantKwest, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Apexigen, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantWorks LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sorrento Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tetra Bio-Pharma Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments